ReviewTherapeutic advances in respiratory disease
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.
Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Omalizumab for pediatric allergic asthma: evidence-based insights on efficacy and safety from a meta-analysis of randomized trials.Frontiers in pharmacology · 2026Pooled it
- Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review.Frontiers in medicine · 2026Pooled it
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies.The Journal of allergy and clinical immunology · 2026Trial
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Treatment of bronchial asthma - A simplified overview.Lung India : official organ of Indian Chest Society · 2026Article
- The identification of biomarkers for response to omalizumab in adult asthma based on untargeted metabolomic analysis.Medicine · 2026Article
- Integrating GPCR Regulation and Calcium Dynamics in Airway Smooth Muscle Function: A Comprehensive Review.Cells · 2026Review
- Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy.Journal of asthma and allergy · 2026Article
- A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma.Frontiers in immunology · 2026Article
- Prevalence and association of elevated total serum IgE levels with ICU admissions and poor asthma control: a retrospective study in a tertiary hospital in Saudi Arabia.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- FDA-Approved Biologics for CRSwNP: A Five-Year Analysis of the FDA Adverse Event Reporting System.Laryngoscope investigative otolaryngology · 2025Article
- Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab.Allergy · 2025Article
- Biologic Therapies for Severe Asthma: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Touching a Nerve: Neuroimmune Interactions in Asthma.Immunological reviews · 2025Review
- A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.Scientific reports · 2025Article
- Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.Annals of medicine · 2024Article
- Paraoxonase-1 Is a Pivotal Regulator Responsible for Suppressing Allergic Airway Inflammation Through Adipose Stem Cell-Derived Extracellular Vesicles.International journal of molecular sciences · 2024Article
- Unlocking Better Asthma Control: A Narrative Review of Adherence to Asthma Therapy and Innovative Monitoring Solutions.Journal of clinical medicine · 2024Review
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.Journal of asthma and allergy · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinity receptors. Therefore, omalizumab effectively blunts the immune response in atopic asthmatic patients, thus significantly improving the control of asthma symptoms and successfully preventing disease exacerbations. These very positive effects of omalizumab make it possible to drastically decrease both referrals to the emergency room and hospitalizations for asthma exacerbations. Such important therapeutic actions of omalizumab have been documented by several randomized clinical trials, and especially by more than 10 years of real-life experience in daily clinical practice. Omalizumab can also interfere with airway remodelling by inhibiting the activation of IgE receptors located on structural cells such as bronchial epithelial cells and airway smooth muscle cells. Moreover, omalizumab is characterized by a very good safety and tolerability profile. Hence, omalizumab represents a valuable therapeutic option for the add-on biological treatment of severe allergic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.